Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe MushroomsField Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in ChicagoCSE Bulletin: New Listing – Psyched Wellness Ltd. (PSYC)HAVN Life Sciences Has Been One Of The Best Performing Stocks In The Psychedelics Sector Over The Past MonthHavn Life Sciences Signs Agreement to Supply Psychedelic Compounds for use in Research and Development to Revive TherapeMindset Pharma Commences In Vivo Program for Its Proprietary Next Generation Psychedelic Drug Candidates and Provides CoCYBIN and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTOWake Network Is Laser Focused On Advancing Fungi-Based Medicine Through Cutting Edge Technology and Clinical ResearchMydecine Innovations Group subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding OpportunitCybin Corp’s Clinical Trials In Jamaica Are Setting The Company Up For A Quicker Route To Market Than Their PeersMindMed Announces $25 Million Bought Deal Public Offering3 Psychedelic Stocks With The Highest Chance Of Successfully Bringing A Psychedelic Therapy To MarketMydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with PsilocybinCompass Pathways and Cybin Corp Are Two Of The Most Compelling Enterprises We Have Seen In The Psychedelics Sector Thus MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies andHavn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of DireHavn Life joins UK Psychedelics Working Group with Leading International ScientistsMind Cure Is Deploying A “5 Sphere” Strategy To Plant Their Flag In The Psychedelics SectorCEO Spotlight: David Kerbel of Rritual MushroomsNuminus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Technical420 Site Search

Returned 16 result(s).

CYBIN and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO

CLARMIN EXPLORATIONS INC. (TSXV: CX.V) and CYBIN CORP. (“ CYBIN ” or the “ Company ”), a life sciences company focused on psychedelic pharmaceutical therapies, announce the closing of a private placement offering by the Company (the “ Offering ) of an aggregate of 60,000,000 subscription receipts (the “ Subscription Receipts ”) at a price of CDN$0.75 per…

Cybin Corp’s Clinical Trials In Jamaica Are Setting The Company Up For A Quicker Route To Market Than Their Peers

As it relates to clinical trials, Cybin is planning and designing clinical trials on major depressive disorder (MDD) and addiction in Jamaica, West Indies. The company is also conducting bioavailability studies on proprietary delivery mechanisms, and we are favorable on how this differentiates Cybin from other psychedelic therapy companies. Cybin…

3 Psychedelic Stocks With The Highest Chance Of Successfully Bringing A Psychedelic Therapy To Market

One of the most exciting growth stories in the biotech sector relates to the studies on psychedelic substances. The companies that focus on this vertical are working to develop treatments for mental illness. We are bullish on this opportunity due to the size of the total addressable market (TAM). Although…

Compass Pathways and Cybin Corp Are Two Of The Most Compelling Enterprises We Have Seen In The Psychedelics Sector Thus Far

A few weeks ago, Compass Pathways (CMPS) completed an initial public offering (IPO) on the Nasdaq. By accomplishing this, Compass became the first psychedelic therapy company to list on a big-board U.S. exchange.   Compass’ IPO was nothing short of significant success, and the listing represented a significant milestone for…

Cybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass Pathways

Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…

CEO Spotlight: Doug Drysdale of Cybin Corp.

Today, we are lucky to have Doug Drysdale - CEO - of Cybin Corp. with us and appreciate you taking the time to educate our readers. Cybin is a leading Life Sciences Company focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors. Congratulations on…

Cybin Corp Announces Doug Drysdale as Chief Executive Officer

Cybin Corp. (the “Company or “Cybin”), a life sciences company advancing psychedelic pharmaceuticals, is pleased to announce that Mr. Doug Drysdale has been appointed as Chief Executive Officer. Doug has more than 30 years of experience in the health care sector. As a skillful corporate director, in early 2014, Doug…

Cybin Corp. Is A Multi-Faceted Life Sciences Company Investors Should Have On Their Radar

Cybin Corp. is a life sciences company that is focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market. The emerging business is laser focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors and has an intellectual property (IP)…

Cybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting Issuer

Cybin Corp. ("Cybin" or the "Company"), a private psilocybin and nutraceutical company is pleased to announce the proposed management team and board of directors of the issuer (the "Resulting Issuer") resulting from the proposed reverse takeover (the "Proposed Transaction") of Clarmin Explorations Inc. (TSX.V: CX) ("Clarmin"), a Tier 2 mining…

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Cybin Corp., Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, is pleased to announce that it has entered into a feasibility agreement with IntelGenx Corp. (OTCQB:IGXT; TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link